Research programme: anticancer therapeutics- QB3@953/GlaxoSmithKline

Drug Profile

Research programme: anticancer therapeutics- QB3@953/GlaxoSmithKline

Alternative Names: anticancer therapeutics- QB3@953/GlaxoSmithKline

Latest Information Update: 15 Feb 2017

Price : $50

At a glance

  • Originator GlaxoSmithKline; QB3@953
  • Developer GlaxoSmithKline; QB3@953; Telo Therapeutics
  • Class Antineoplastics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 02 Feb 2017 Preclinical trials in Cancer in USA (unspecified route)
  • 02 Feb 2017 Telo Therapeutics and GlaxoSmithKline enters into an oncology-focused research collaboration agreement
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top